Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

MRK vs EQ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRK Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

MRK Overall Winner 6-Pillar Tally: MRK 5 – 1 EQ Matrix Metrics: MRK 8 – 2 EQ

As of Nov 19, 2026, Merck & Co., Inc. (MRK) is the stronger overall head-to-head candidate over Equillium, Inc. (EQ) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MRK carries a Unified Composite Score of 50.8/100 (HOLD) at $132.81 (14.8x Forward P/E, 35.2% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: MRK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRK vs EQ
MRK NYSE Head-to-Head Winner
Merck & Co., Inc.
Pharmaceutical Preparations
$132.81
-3.61% 1D
Market Cap $339.7B
TTM Revenue $67.4B
Forward P/E 14.8x
Beta / 30D Vol 0.27β · 34% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.7%), weak momentum, RSI 32
RSI-14: 32.2 · SMA20: $144.93 · SMA50: $145.48
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
TTM Revenue $4.4M
Forward P/E 1.5x
Beta / 30D Vol 1.53β · 93% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.8%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $1.33 · SMA50: $1.49

6-Pillar Scorecard Institutional Category Breakdown (MRK 5 – 1 EQ)

Columns: Metric · MRK · EQ
1. Valuation Multiples EQ
Forward P/E 14.8x 1.5x
Trailing P/E 139.2x 1.5x
PEG Ratio 3.47x N/M
EV / Revenue 5.7x 7.7x
2. Growth & Scale MRK
Revenue Growth (YoY) +4.7% -52.3%
Earnings Growth (YoY) -12.0% +0.0%
TTM Revenue (USD) $67.4B $4.4M
Market Cap $339.7B $90.6M
3. Profitability & Quality MRK
Gross Margin 75.2% 100.0%
Operating Margin 35.2% 0.0%
Net Profit Margin 3.6% 0.0%
Return on Equity (ROE) 5.1% -59.0%
4. Balance Sheet & Cash Flow MRK
Cash Generation (TTM) $14.7B -$20M
Cash Flow Margin 21.9% N/A
Net Cash / Leverage $44.2B Net Debt (1.20x D/E) $57M Net Cash
Dividend Yield 2.34% None (0.00%)
5. Options & Positioning MRK
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 30.6% (28th %ile) 261.3% (100th %ile)
Put/Call OI Skew 0.80x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat MRK
OpEx & R&D Intensity 40.0% of Rev ($27.0B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRK (8) vs EQ (2)
Institutional Metric MRK EQ Criterion Row Edge
Market Capitalization
Scale
$339.7B $90.6M Larger Scale MRK
Trailing P/E Ratio
Valuation
139.2x 1.5x Lower Multiple EQ
Forward P/E Ratio
Valuation
14.8x 1.5x Lower Multiple EQ
Revenue Growth (YoY)
Growth
+4.7% -52.3% Higher Growth MRK
Operating Margin (TTM)
Profitability
35.2% 0.0% Higher Margin MRK
Net Profit Margin
Profitability
3.6% 0.0% Higher Margin MRK
Return on Equity (ROE)
Capital Efficiency
5.1% -59.0% Higher ROE MRK
52-Week Range Position
Momentum
63% ($92–$157) 11% ($1–$4) Stronger Trend MRK
Beta / 30D Volatility
Risk Regime
0.27β · 34% Vol 1.53β · 93% Vol Lower Realized Risk MRK
Unified Institutional Score
Composite Signal
50.8 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite MRK
Trailing 12M Revenue (USD)
Operating Scale
$67.4B $4.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.47x PEG · 5.7x EV/Rev N/M PEG · 7.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$14.7B ($44.2B Net Debt (1.20x D/E)) -$20M ($57M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRK +9.74 pp
MRK: -11.39% · EQ: -21.13%
3M Horizon MRK +38.58 pp
MRK: -12.94% · EQ: -51.52%
6M Horizon MRK +63.93 pp
MRK: +14.61% · EQ: -49.32%
1Y Horizon MRK +25.73 pp
MRK: +37.73% · EQ: +12.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MRK Revenue EQ Revenue MRK Op. Margin EQ Op. Margin Margin Leader
FY2018 $42.3B N/A 14.7% N/A MRK
FY2019 $39.1B N/A 25.2% N/A MRK
FY2020 $41.5B N/A 17.0% N/A MRK
FY2021 $48.7B N/A 26.8% N/A MRK
FY2022 $59.3B $20M 24.5% -393.9% MRK
FY2023 $60.1B $40M 0.6% -40.2% MRK
FY2024 $64.2B $40M 26.7% -20.1% MRK
FY2025 $65.0B N/A 28.1% N/A MRK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRK CONSOLIDATION
61d in phase · OBV DISTRIBUTION
Current IV 30.6%
IV Percentile 28th %ile
Put/Call OI Skew 0.80x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 261.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $144.46 · IV 31.1%

MRK Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($14,446)

Compare $14,446 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 31.1% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $145 / $155 Bull Call Spread

Buy 1x $145C · Sell 1x $155C · 31d

Net Entry $340 Debit
T+5d @ +5% Move +$221 (+65%)
Max Risk / Buffer $340 Capped
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $135 / $125 Bull Put Spread

Sell 1x $135P · Buy 1x $125P · 31d

Net Entry $149 Credit
Max Credit / Yield +$149 (+17.5% RoM)
Max Risk / Buffer -7.6% Cushion ($851 Mgn)
5d Edge & Liquidity 78% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq B

Asymmetric 1x1x1 ($145C + $143/$130P)

+1x 17d $143P · -1x 59d $130P · +1x 31d $145C

Net Entry $504 Debit
T+5d @ +5% Move +$343 (+16.1% RoM)
Max Risk / Buffer -10.0% Put Cushion ($2,125 Mgn)
5d Edge & Liquidity 9.9x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRK Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $339.7B market capitalization and 35.2% operating margin.
OpEx & R&D Reinvestment 40.0% of Rev ($27.0B)
90D Engineering Disclosures 0 Published
EQ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $90.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MRK vs EQ Key Questions & Quantitative Answers

As of Nov 19, 2026, Merck & Co., Inc. (MRK) is the stronger overall head-to-head candidate over Equillium, Inc. (EQ) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MRK carries a Unified Composite Score of 50.8/100 (HOLD) at $132.81 (14.8x Forward P/E, 35.2% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: MRK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRK leads the Growth & Scale pillar: MRK posts +4.7% YoY revenue growth and -12.0% YoY earnings growth on $67.4B TTM revenue (75.2% gross margin, 35.2% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRK cumulative revenue shifted +53.7% while EQ shifted +100.0%. In operating R&D and SG&A reinvestment, MRK deploys 40.0% of Rev ($27.0B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.

EQ screens cheaper on headline valuation multiples. MRK trades at 14.8x Forward P/E, 139.2x Trailing P/E, 3.47x PEG, and 5.7x EV/Revenue (21.9% FCF margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRK (5.1% ROE) versus EQ (-59.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MRK carries 30.6% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.80x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 34% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.